The court narrowed the case by dismissing several theories, but left the core DAW campaign, PBM exclusivity, and reclassification petition claims intact — these will proceed to discovery and potentially trial. The case now focuses on Teva's alleged false statements to doctors and exclusionary PBM contracting, which could eventually lead to behavioral remedies or damages. Monitor the related In re Copaxone Antitrust Litigation (No. 22-1232) for parallel developments. Teva's OTC-traded stock may see limited near-term movement as this is a single district court ruling on a motion to dismiss, not a final judgment.
Price Chart
Executive Summary
The District of New Jersey adopted a Special Master's recommendation to partially dismiss Mylan's antitrust lawsuit against Teva regarding Copaxone. The ruling dismissed claims that Teva's 20mg citizen petitions, 20mg ANDA lawsuit, 2014 FDA lawsuit, 40mg ANDA lawsuit, market-shift strategy, and copay assistance program were anticompetitive, finding they were protected by Noerr-Pennington immunity or failed to plausibly allege causation. However, the court allowed Mylan's claims regarding Teva's DAW (Dispense as Written) campaign, exclusionary agreements with PBMs, and the 2020 reclassification petition to proceed, meaning significant antitrust exposure remains for Teva.
Court Ruling Details
Key Facts
- Court adopted Special Master's 91-page R&R partially granting Teva's motion to dismiss Mylan's antitrust complaint
- DAW campaign allegations, exclusionary PBM agreement allegations, and 2020 reclassification petition claims survive dismissal and will proceed to discovery
- 20mg citizen petitions, 20mg and 40mg ANDA lawsuits, 2014 FDA lawsuit, market-shift allegations, and copay assistance program allegations dismissed with prejudice under Noerr-Pennington immunity
- Non-Orange Book patent litigation allegations excluded from complaint as not pled in original filing
- Foreign regulatory conduct allegations struck from complaint as irrelevant to Sherman Act claims
- Lanham Act false advertising claim (Count II) and state law claims (Counts III-VI) also survive
- Copaxone is a $4B+ annual revenue drug for Teva; generic competition via Mylan has been limited since 2017 launch
Financial Impact
No damages awarded. If Mylan eventually wins, potential antitrust damages could be substantial (trebled), but no dollar figure stated in the opinion. Copaxone represented approximately $1.5B in annual Teva revenue as of recent periods.
Risk Factors
- Surviving claims (DAW campaign, PBM agreements, reclassification petition) will now proceed to costly discovery
- If Mylan prevails at trial, treble damages under antitrust laws could be material given Copaxone's revenue base
- Related multi-district litigation (In re Copaxone Antitrust Litig.) may compound exposure
- DOJ anti-kickback investigation into Teva's copay assistance (referenced in complaint) remains a separate risk
- Appeal by Mylan on dismissed claims is possible but faces high bar given de novo review and factual findings
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-15mpe8hi-TEVA |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | Press Release | $36.35 $39.19 | ▲ +7.81% | ▲ +8.31% | $39.51 (+8.69%) |
Sep 8, 2026 24d ago | 424B5 | $36.76 $39.25 | ▲ +6.77% | ▲ +7.89% | $39.51 (+7.48%) |
Sep 2, 2026 4w ago | Court Ruling | $37.49 $36.35 | ▼ −3.04% | ▼ −2.08% | $39.51 (+5.39%) |
Aug 28, 2026 5w ago | Press Release | $36.44 $36.36 | ▼ −0.22% | ▼ −0.33% | $39.51 (+8.42%) |
Aug 25, 2026 5w ago | Court Ruling | $38.10 $36.20 | ▼ −4.99% | ▼ −4.46% | $39.51 (+3.70%) |
Aug 25, 2026 5w ago | Insider Cluster | $38.10 $36.20 | ▼ −4.99% | ▼ −4.46% | $39.51 (+3.70%) |
Aug 10, 2026 7w ago | Insider Cluster | $36.14 $36.46 | ▲ +0.89% | ▲ +0.93% | $39.51 (+9.32%) |
Aug 5, 2026 8w ago | Insider Cluster | $34.81 $36.45 | ▲ +4.70% | ▲ +3.49% | $39.51 (+13.50%) |
Jul 31, 2026 9w ago | Court Ruling | $35.01 $35.36 | ▲ +1.00% | ▼ −2.51% | $39.51 (+12.85%) |
Jul 29, 2026 9w ago | 8-K | $34.71 $34.72 | ▲ +0.03% | ▼ −5.50% | $39.51 (+13.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access